◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Hikal Limited (HIKAL) Financial History

Name: Hikal Limited (HIKAL) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Hikal Limited (HIKAL) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Navi Mumbai, India with about 2,152 employees. Its market capitalization is roughly ₹28 billion. In the fiscal year ended 2026-03-31, HIKAL reported ₹17.0B in revenue and (₹488M) in net income.

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries.

Interactive charts & full statements →

HIKAL Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹17.0B	₹18.4B	₹17.7B	₹20.0B
Gross Profit	₹9.0B	₹9.7B	₹9.0B	₹8.6B
Operating Income (EBIT)	₹577M	₹1.9B	₹1.5B	₹1.5B
Net Income	(₹488M)	₹908M	₹696M	₹784M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HIKAL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹4.0B	₹5.2B	₹4.9B	₹3.2B	₹3.7B	—
Gross Profit	₹2.2B	₹3.0B	₹2.6B	₹1.9B	₹1.8B	—
Operating Income (EBIT)	(₹57M)	₹634M	₹415M	(₹340M)	(₹143M)	—
Net Income	(₹74M)	₹144M	(₹59M)	(₹349M)	(₹224M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HIKAL Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹123M)	(₹148M)	(₹148M)	(₹123M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HIKAL Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Assets	₹23.7B	₹25.3B	₹24.9B	₹23.9B
Total Liabilities	₹11.7B	₹12.7B	₹13.0B	₹12.5B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HIKAL viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

9273 · Koa Shoji Holdings Co.,Ltd. — JPY 32 billion
MEGA · Mega Lifesciences Public Company Limited — THB 31 billion
SDZ · Sandoz Group AG — CHF 30 billion
2096 · Simcere Pharmaceutical Group Limited — HK$29 billion
3320 · China Resources Pharmaceutical Group Limited — HK$27 billion
0867 · China Medical System Holdings Limited — HK$27 billion
SAKAR · Sakar Healthcare Limited — ₹26 billion
SHUKRAPHAR · Shukra Pharmaceuticals Limited — ₹25 billion

← HIK All “H” companies HILINFRA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.